March 3, 2020 / 11:05 AM / 3 months ago

BRIEF-Novartis Receives Health Canada Approval For Mayzent

March 3 (Reuters) - NOVARTIS AG:

* RECEIVES HEALTH CANADA APPROVAL FOR MAYZENT™ (SIPONIMOD) TO TREAT SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS WITH ACTIVE DISEASE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below